Table 5: rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month [87, 91] or 42 days [90] after one dose of MenACWY-TT in toddlers (ATP immunogenicity cohort).

ReferenceAge groupVaccine 𝑁 %≥1 : 8 [95% CI]%≥1 : 128 [95% CI]GMT [95% CI]

rSBA-MenA

Knuf et al., 2010 [87]12–14 monthsMenACWY-TT42100 [91.6–100]100 [91.6–100]5665.2 [4086.0–7854.9]
Vesikari et al., 2011 [90]12–23 monthsMenACWY-TT35499.7 [98.4–100]99.7 [98.4–100]2205.0 [2007.8–2421.6]
MenACWY-TT + MMRV360100 [99.0–100]99.7 [98.5–100]2085.9 [1905.3–2283.6]
Knuf et al., 2011 [91]12–23 monthsMenACWY-TT18398.4 [95.3–99.7]97.8 [94.5–99.4]3169.9 [2577.2–3898.8]
MenACWY-TT*178100 [97.9–100]100 [97.9–100]1938.3 [1699.1–2211.2]
MenACWY-TT + DTPa-HBV-IPV/Hib193100 [98.1–100]100 [98.1–100]3152.9 [2752.5–3611.4]

rSBA-MenC

Knuf et al., 2010 [87]12–14 monthsMenACWY-TT42100 [91.6–100]95.2 [83.8–99.4]983.5 [718.7–1345.9]
MenC-CRM1974697.8 [88.5–100]87.0 [73.7–95.1]372.5 [257.7–538.4]
Vesikari et al., 2011 [90]12–23 monthsMenACWY-TT35499.7 [98.4–100]95.8 [93.1–97.6]477.6 [437.3–521.6]
MenACWY-TT + MMRV357100 [99.0–100]94.4 [91.5–96.5]519.0 [470.9–571.9]
MenC-CRM19712197.5 [92.9–99.5]70.2 [61.3–78.2]212.3 [170.0–265.2]
Knuf et al., 2011 [91]12–23 monthsMenACWY-TT18397.3 [93.7–99.1]94.0 [89.5–97.0]828.7 [672.4–1021.4]
MenACWY-TT*178100 [97.9–100]88.2 [82.5–92.5]386.0 [333.9–446.2]
MenACWY-TT + DTPa-HBV-IPV/Hib191100 [98.1–100]99.0 [96.3–99.9]879.7 [763.1–1014.0]
MenC-CRM19711498.2 [93.8–99.8]89.5 [82.3–94.4]691.4 [520.8–917.9]

rSBA-MenW-135

Knuf et al., 2010 [87]12–14 monthsMenACWY-TT43100 [91.8–100]100 [91.8–100]3975.2 [3065.7–5154.5]
Vesikari et al., 2011 [90]12–23 monthsMenACWY-TT354100 [99.0–100]99.4 [98.0–99.9]2681.7 [2453.1–2931.6]
MenACWY-TT + MMRV360100 [99.0–100]100 [99.0–100]2055.8 [1871.0–2258.9]
Knuf et al., 2011 [91]12–23 monthsMenACWY-TT18698.4 [95.4–99.7]96.8 [93.1–98.8]4022.3 [3269.2–4948.8]
MenACWY-TT*179100 [98.0–100]99.4 [96.9–100]2466.4 [2175.4–2796.4]
MenACWY-TT + DTPa-HBV-IPV/Hib193100 [98.1–100]100 [98.1–100]4147.0 [3670.1–4685.8]

rSBA-MenY

Knuf et al., 2010 [87]12–14 monthsMenACWY-TT42100 [91.6–100]100 [91.6–100]2295.1 [1701.5–3095.8]
Vesikari et al., 2011 [90]12–23 monthsMenACWY-TT354100 [99.0–100]99.7 [98.4–100]2729.4 [2472.7–3012.8]
MenACWY-TT + MMRV359100 [99.0–100]99.7 [98.5–100]2282.4 [2051.3–2539.5]
Knuf et al., 2011 [91]12–23 monthsMenACWY-TT18597.3 [93.8–99.1]96.2 [92.4–98.5]3167.7 [2521.9–3978.9]
MenACWY-TT*17999.4 [96.9–100]99.4 [96.9–100]2446.9 [2088.5–2866.8]
MenACWY-TT + DTPa-HBV-IPV/Hib192100 [98.1–100]100 [98.1–100]3461.8 [2990.1–4007.9]

𝑁 : numbers of subjects with available data, %: percentage of subjects with titre within the specified range, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, *MenACWY-TT given one month after DTPa-HBV-IPV/Hib vaccine, Results of this table were previously published [87, 90, 91].